Compounds > 5'-palmitoyl cytarabine
Page last updated: 2024-12-06

5'-palmitoyl cytarabine

Cross-References

ID SourceID
PubMed CID41566
CHEMBL ID3350506
SCHEMBL ID3828257
MeSH IDM0052892

Synonyms (20)

Synonym
55726-45-9
brn 0727729
n(4)-palmitoyl cytarabine
1-beta-d-arabinofuranosyl-n(sup 4)-palmitoylcytosine
n(sup 4)-palmitoyl-1-beta-d-arabinofuranosylcytosine
cytosine, 1-beta-d-arabinofuranosyl-n(sup 4)-palmitoyl-
n-[1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide
plac
o57a51je0d ,
unii-o57a51je0d
nsc 250684
pl-ac
n4-palmitoyl-1-beta-d-arabinofuranosylcytosine
n4-palmitoyl-1-.beta.-d-arabinofuranosylcytosine
n4-palmitoyl cytarabine
XEFNBUBDJCJOGM-OUJCMCIWSA-N
n4 -palmitoyl-1-beta-d-arabinofuranosylcytosine
SCHEMBL3828257
CHEMBL3350506
Q27285356

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" No clear daily dose-response was noted."( [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
Kimura, K; Ohno, R, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID96841Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 200 mg/kg (treatment of 1qd schedule) dosage; Range is 14-231986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96549Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153306Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (1 qd treatment schedule) dosage; >45.0/12.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96701Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 300 mg/kg (1 qd treatment schedule) dosage; Range is 14-181986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID98958Antitumor activity against the ip implanted L1210 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152682Antitumor activity against the ip implanted P388 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153000Antitumor activity was determined against the ip implanted P388 leukemia in mice by 45-day survivors in mice at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97105Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 300 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97224Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 100-2501986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID154854Antitumor activity was determined against the ip implanted P388 leukemia in mice by change in tumor weight at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152822Antitumor activity was determined against the ip implanted P388 leukemia in mice by range in survival days at 200 mg/kg (1 qd treatment schedule) dosage; Range is 24->451986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96543Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 300 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97618Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent median survival rate (treated/control) at 300 mg/kg (1 qd treatment schedule) dosage; 14.5/7.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97288Antitumor activity was determined against the ip implanted L1210 leukemia in mice by 45-day survivors in mice at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97112Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97627Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (treatment of 1qd schedule) dosage; 19.5/7.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153284Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent increase in life span at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152368Antitumor activity against ip implanted P388 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 200-3001986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID100492Antitumor activity against the ic implanted L1210 lymphoid leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews1 (8.33%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other9 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cytarabine
[no description available]		6.32121beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
enocitabine
[no description available]		4.8521organic molecular entity
aclarubicin
Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.		4.8521aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
5'-oleoyl cytarabine
elaidic acid-cytarabine: a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine		1.9610pyrimidine nucleoside
edelfosine
(R)-edelfosine : A 1-octadecyl-2-methylglycero-3-phosphocholine that is the (R)-enantiomer of edelfosine.		1.96101-octadecyl-2-methylglycero-3-phosphocholine
pirarubicin
[no description available]		4.8521anthracycline
arabinofuranosyluracil
Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.6630
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.3720
Leucocythaemia
[description not available]		05.1841
Acute Disease
Disease having a short and relatively severe course.		04.6721
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		05.1841
Leukemia, Lymphocytic
[description not available]		01.9610
Germinoblastoma
[description not available]		01.9610
Acute Myelogenous Leukemia
[description not available]		01.9610
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9610
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		01.9610
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		01.9610
Adenocarcinoma, Basal Cell
[description not available]		01.9610
Cancer of Colon
[description not available]		01.9610
Cancer of Lung
[description not available]		01.9610
Malignant Melanoma
[description not available]		02.3720
Experimental Neoplasms
[description not available]		01.9610
Experimental Mammary Neoplasms
[description not available]		01.9610
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9610
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.3720
Blood Diseases
[description not available]		01.9710
Erythremia
[description not available]		01.9710
Hematologic Diseases
Disorders of the blood and blood forming tissues.		01.9710
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.		01.9710
Chromosome Inversion
An aberration in which a chromosomal segment is deleted and reinserted in the same place but turned 180 degrees from its original orientation, so that the gene sequence for the segment is reversed with respect to that of the rest of the chromosome.		01.9710
Myelomonocytic Leukemia, Chronic
[description not available]		01.9710
Leukemia, Myelomonocytic, Chronic
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.		01.9710
Dysmyelopoietic Syndromes
[description not available]		01.9710
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		02.3720
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		01.9710
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		02.3720
Benign Neoplasms
[description not available]		01.9710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9710
chemdatabank.com